[Federal Register Volume 84, Number 133 (Thursday, July 11, 2019)]
[Notices]
[Page 33078]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-14779]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-2836]


Allergenic Products Advisory Committee; Notice of Meeting; 
Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
entitled ``Allergenic Products Advisory Committee; Notice of Meeting'' 
that appeared in the Federal Register of June 24, 2019. The document 
announced a forthcoming public advisory committee meeting of the 
Allergenic Products Advisory Committee. The document was published with 
the incorrect name of the committee in the Agenda portion of the 
notice. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Capt. Serina Hunter-Thomas or Ms. 
Monique Hill, Center for Biologics Evaluation and Research, Food and 
Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6338, 
Silver Spring, MD 20993-0002, 240-402-5771, [email protected] or 301-796-4620, [email protected], 
respectively; or FDA Advisory Committee Information Line, 1-800-741-
8138 (301-443-0572 in the Washington, DC area).

SUPPLEMENTARY INFORMATION: In the Federal Register of Monday, June 24, 
2019, 84 FR 29524, in FR Doc. 2019-13354, the following correction is 
made:
    On page 29525, in the first column, under the headings, 
SUPPLEMENTARY INFORMATION and ``Agenda'', the first sentence is 
corrected to read ``On September 13, 2019, the Center for Biologics 
Evaluation and Research (CBER) Allergenic Products Advisory Committee 
(APAC) will meet in open session to discuss and make recommendations on 
the safety and efficacy of Peanut (Arachis hypogaea) Allergen Powder 
manufactured by Aimmune Therapeutics, Inc., indicated for treatment to 
reduce the risk of anaphylaxis after accidental exposure to peanut in 
patients aged 4 to 17 years with a confirmed diagnosis of peanut 
allergy.''

    Dated: July 8, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-14779 Filed 7-10-19; 8:45 am]
 BILLING CODE 4164-01-P